NEEDHAM, Massachusetts – July 30, 2012– Cambridge Healthtech Associates™ (CHA™), today announced results of industry survey of biotech and pharmaceutical companies on the use of safety biomarkers in the development of new medications.
Recently, Cambridge Healthtech Associates, through the Drug Safety Executive Council™ (DSEC™), completed interviews with preclinical safety experts from large and small biotech and pharmaceutical companies, focusing on middle and senior level managers in preclinical safety and toxicology groups.
The goal of the research was to identify trends in biomarkers and their utilization in these top tier companies. The survey builds on CHA’s seven year history of technology evaluation projects in the life sciences.
Ernie Bush, Ph.D., Scientific Director in drug safety and development, for DSEC and CHA, led this research project. Dr. Ernie Bush has nearly 30 years of biomedical research, focused on:
Preclinical safety assessment; and the
Navigation, evaluation and prioritization of biopharmaceutical research initiatives.
Some of the key findings of the safety biomarkers research include the following:
Biomarkers of organ toxicity are consistently rated as one of the most desired new tools by this industry segment. In this current study, most interviewees found the inclusion of systems or pathway modeling into the selection and interpretation of safety biomarkers to be an attractive new element. We have also seen this pattern emerge in CHA’s annual New Technology Adoption surveys.
“We are always interested in trends in the life sciences industry and our recent surveys indicate a growing interest in the use of biomarkers in early drug safety testing. We believe this is one of several areas of growth for the future,” said Dawn Van Dam, General Manager for Cambridge Healthtech Associates and the Drug Safety Executive Council.
About Cambridge Healthtech Associates Cambridge Healthtech Associates™ (CHA™) uses its unique collaborative model to improve the speed, economics and effectiveness of life science research and development, leveraging its consulting, technology evaluations and communities to help clients in the industry penetrate the marketplace and increase revenue. Read more at www.chacorporate.com.
About the Drug Safety Executive Council
The Drug Safety Executive Council™ (DSEC™) is an online community focused on the development of better and safer medicines. DSEC is a platform for biopharmaceutical companies, contract research organizations and academics to share knowledge and exchange ideas on improving the drug pipeline. DSEC™ is managed by Cambridge Healthtech Associates™ (CHA™). Read more at www.drugsafetycouncil.org.